It is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA
The neurobiological mechanisms underlying the benefits of combined GLP-1R and GIPR agonism achieved from compounds like tirzepatide remains to be fully delineated
On one hand, GLP-1 receptor agonists delivered strong A1C reduction, meaningful weight loss, and cardiovascular benefit
Key Takeaways Prescribers and pharmacies will submit prior authorization requests and claims to a CMS contractor, not Part D plans or their PBMs Detailed conditions for beneficiary eligibility specified Patients will have a copay of $50, but pharmacy reimbursement details remain to be specified Background on the BALANCE Model CMS announced the BALANCE Model in December of last year, in which CMS will negotiate directly with manufacturers on behalf of Part D plan sponsors and state Medicaid agencies for more favorable costs and terms for GLP-1 medications
Do not purchase medications that are sold online without any labels
MS confirms the precise molecular weight of the peptide, confirming that the compound in the vial is authentically the 39-amino-acid sequence of Retatrutide and has not been substituted with a cheaper, structurally distinct sequence like metabolic research peptides or metabolic research peptides